Metal-dependent inhibition of HIV-1 integrase by β-diketo acids and resistance of the soluble double-mutant (F185K/C280S)

被引:118
作者
Marchand, C
Johnson, AA
Karki, RG
Pais, GCG
Zhang, XC
Cowansage, K
Patel, TA
Nicklaus, MC
Burke, TR
Pommier, Y
机构
[1] NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Med Chem Lab, Ctr Canc Res, Frederick, MD 21701 USA
关键词
D O I
10.1124/mol.64.3.600
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The beta-diketo acids (DKAs) represent a major advance for anti HIV-1 integrase drug development. We compared the inhibition of HIV-1 integrase by six DKA derivatives using the wild-type enzyme or the double-mutant F185K/C280S, which has been previously used for crystal structure determinations. With the wild-type enzyme, we found that DKAs could be classified into two groups: those similarly potent in the presence of magnesium and manganese and those potent in manganese and relatively ineffective in the presence of magnesium. Both the aromatic and the carboxylic or tetrazole functions of DKAs determined their metal selectivity. The F185K/C280S enzyme was markedly more active in the presence of manganese than magnesium. The F185K/C280S integrase was also relatively resistant to the same group of DKAs that were potent in the presence of magnesium with the wild-type enzyme. Resistance was caused by a synergistic effect from both the F185K and C280S mutations. Molecular modeling and docking suggested metal-dependent differences for binding of DKAs. Molecular modeling also indicated that the tetrazole or the azido groups of some derivatives could directly chelate magnesium or manganese in the integrase catalytic site. Together, these experiments suggest that DKAs recognize conformational differences between wild-type and the double-mutant HIV-1 integrase, because they chelate the magnesium or manganese in the enzyme active site and compete for DNA binding.
引用
收藏
页码:600 / 609
页数:10
相关论文
共 60 条
[41]   Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition [J].
Miller, MD ;
Farnet, CM ;
Bushman, FD .
JOURNAL OF VIROLOGY, 1997, 71 (07) :5382-5390
[42]   Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga [J].
Neamati, N .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (05) :709-724
[43]   Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors [J].
Pais, GCG ;
Zhang, XC ;
Marchand, C ;
Neamati, N ;
Cowansage, K ;
Svarovskaia, ES ;
Pathak, VK ;
Tang, Y ;
Nicklaus, M ;
Pommier, Y ;
Burke, TR .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (15) :3184-3194
[44]   Modeling HIV-1 integrase complexes based on their hydrodynamic properties [J].
Podtelezhnikov, AA ;
Gao, K ;
Bushman, FD ;
McCammon, JA .
BIOPOLYMERS, 2003, 68 (01) :110-120
[45]   HIV-1 integrase as a target for antiviral drugs [J].
Pommier, Y ;
Pilon, AA ;
Bajaj, K ;
Mazumder, A ;
Neamati, N .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1997, 8 (06) :463-483
[46]  
PRIET S, 2003, J BIOL CHEM
[47]   HIV chemotherapy [J].
Richman, DD .
NATURE, 2001, 410 (6831) :995-1001
[48]   Integracides:: Tetracyclic triterpenoid inhibitors of HIV-1 integrase produced by Fusarium sp. [J].
Singh, SB ;
Zink, DL ;
Dombrowski, AW ;
Polishook, JD ;
Ondeyka, JG ;
Hirshfield, J ;
Felock, P ;
Hazuda, DJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (07) :1577-1582
[49]   Four novel bis-(naphtho-γ-pyrones) isolated from Fusarium species as inhibitors of HIV-1 integrase [J].
Singh, SB ;
Zink, DL ;
Bills, GF ;
Teran, A ;
Silverman, KC ;
Lingham, RB ;
Felock, P ;
Hazuda, DJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) :713-717
[50]  
SKALKA AM, 1999, RETROVIRAL INTEGRATI